Clinical Trial Update: Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers [Phase 4]

View source ↗

Summary

An open-label extension in a Phase 4 study is used to evaluate the safety and efficacy of Grafix for chronic diabetic foot ulcers. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcers

Drugs mentioned

• Grafix

Snippet

Sponsor: Osiris Therapeutics | Conditions: Diabetic Foot Ulcers | Phase 4 | Status: COMPLETED